Breaks Categories: News

TuesdayApr 02, 2024 2:50 pm

NetworkNewsBreaks – HealthLynked Corp. (HLYK) Releases Q4, FY 2023 Financial Report Reflect Focus on Core Healthcare Network

HealthLynked (OTCQB: HLYK), a leader in healthcare networking and technological innovation, is reporting financial results for Q4 and full year ended Dec. 31, 2023. A highlight of the report includes that, based on “strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.” The report noted that the company’s strategic focus and technological innovations are paving the way for an optimistic outlook with optimization of operational expenses leading to a 52% cut in operational losses. In…

Continue Reading

TuesdayApr 02, 2024 2:13 pm

NetworkNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Receives Orders from Established Monitoring Provider for Justice, Behavioral Health Use

SOBRSafe (NASDAQ: SOBR), providers of next-generation, transdermal alcohol-detection solutions, has filled purchase orders from Lake Erie Interlock Inc. for both SOBRcheck and SOBRsure devices. According to the announcement, Lake Erie Interlock has “further diversified and expanded its service offering in Ohio” with SOBR solutions, offering point-of-care screening through SOBRcheck and continuous monitoring through SOBRsure throughout the state. The company will be serving probation officers, treatment centers, sober living centers and more. “Since our founding in 1993, our main focus has been on serving customers dealing with the aftermath of alcohol-related problems,” said Lake Erie Interlock president Richard Friedman in the…

Continue Reading

TuesdayApr 02, 2024 1:45 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) in a humanized mouse model. “These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies,” said Rodney Varner, president, chairman and CEO at Genprex. “We…

Continue Reading

TuesdayApr 02, 2024 1:26 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Files Q4, Year-End 2023 Financial Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has filed its audited annual financial results. According to the announcement, the results are for Q4 and the full fiscal year for the period ending Dec. 31, 2023. The company also announced that it had filed accompanying management's discussion and analysis. To view the full press release, visit https://nnw.fm/Cw6Pt About FSD Pharma Inc. FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment…

Continue Reading

TuesdayApr 02, 2024 1:09 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report included that Berubicin, the company’s lead program, has passed preplanned interim futility analysis milestones with a recommendation to proceed without modification into a potentially pivotal glioblastoma multiforme (“GBM”) study, and enrollment for the Berubicin study has been completed with topline data expected in first half…

Continue Reading

TuesdayApr 02, 2024 12:56 pm

NetworkNewsBreaks – Upstream Highlights Ability of Airdrops to Unlock Potential for Brands, Companies and Audiences

Upstream, a MERJ Exchange market and trading app, has published a blog article that discusses the exciting possibilities in the world of digital collectibles. Among these is the ability for airdrops to unlock potential for brands, companies and their audiences. The piece reads, “Airdrops serve as not just a gateway to the exciting world of Web3, but a way to interact with your fans… Build Your Online Presence: Reward your biggest fans with digital rewards or collectibles tied to specific events, locations, milestones, content, etc. These collectibles introduce digital ownership and can decorate your online persona and your fans’ online…

Continue Reading

TuesdayApr 02, 2024 11:49 am

NetworkNewsBreaks – SUIC Worldwide Holdings Ltd (SUIC) Engages IBN for Corporate Communications Expertise, Enters Strategic Agreement

SUIC Worldwide Holdings (OTC: SUIC), a provider of research and development, venture financing and investment for private and public companies, announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Seeking to enhance and streamline existing processes and establish new and exciting business models, SUIC Worldwide Holdings targets investment in companies operating in the areas of internet of things (“IoT”), cloud computing, mobile payments, big data, blockchain, artificial intelligence and global franchising. As part of the client partner relationship, IBN will generate greater awareness for…

Continue Reading

MondayApr 01, 2024 4:15 pm

NetworkNewsBreaks – Alta Global Group Limited Releases Information on Public Offering Pricing

Alta Global (NYSE American: MMA) is reporting on the pricing of its initial public offering. The offering consists of 1,300,000 ordinary shares at $5 per share. The offering, which is expected to close on April 2, 2024, is estimated to result in $6.5 million in gross proceeds before standard deductions and expenses. The announcement also noted that Alta Global granted the underwriters a 45-day option to purchase up to an additional 195,000 ordinary shares; the option was granted to cover any overallotments at the public offering price. A technology company, Alta Global is enabling the global martial arts and combat…

Continue Reading

MondayApr 01, 2024 3:43 pm

NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2023 Financial Report, Operational Update

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for Q4 and full year 2023, for the period ended Dec. 31, 2023. The report noted that revenue came in at $3.2 million for Q4 2023 and $13.8 million for the full year; gross profit was $2.1 million for the Q4 2023 and $8.3 million for the full year; and gross margin totaled 64% for Q4 2023 and 60% for the full year. In addition, the company reported…

Continue Reading

MondayApr 01, 2024 3:33 pm

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate update. The report noted POAI experienced a net loss of some $14 million on total revenue of approximately $1.8 million for the year; the company also reported a 50% reduction in basic and diluted net loss per common share for the full year 2023. In…

Continue Reading